Antibodies binding to cd3 and folr1
AssigneeHoffmann-La Roche Inc.
InventorsPeter BRUENKER, Martina GEIGER, Christian KLEIN, Alexander KNAUPP
Life of this patent
Estimating the term…
Abstract
The present invention generally relates to bispecific antibodies that bind to CD3 and Folate Receptor 1 (FolR1), e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
Claims49
A bispecific antibody that binds to CD3 and Folate receptor 1 (FolR1), wherein the bispecific antibody comprises;
- (i) a first antigen binding domain capable of specific binding to CD3, comprising a heavy chain variable region (VH) comprising a heavy chain complementary determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO:
- 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO:
- 5, and a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:
- 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO:
- 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO:
- 10, and
- (ii) a second antigen binding domain capable of specific binding to FolR1, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO:
- 124, an HCDR 2 comprising the amino acid sequence of SEQ ID NO:
- 125, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO:
- 126, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:
- 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO:
- 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO:
- 10.
A bispecific antibody that binds to CD3 and FolR1, wherein the bispecific antibody comprises:
- (i) a first antigen binding domain capable of specific binding to CD3, comprising a VH comprising the amino acid sequence of SEQ ID NO:
- 7 and a VL comprising the amino acid sequence of SEQ ID NO:
- 11, and
- (ii) a second antigen binding domain capable of specific binding to FolR1, comprising a VH comprising the amino acid sequence of SEQ ID NO:
- 123 and a VL comprising the amino acid sequence of SEQ ID NO:
- 11.
(canceled)
(canceled)
(canceled)
(canceled)
A bispecific antibody comprising:
- (i) a first antigen binding domain capable of specific binding to CD3, comprising a VH comprising an HCDR 1 comprising the amino acid sequence of SEQ ID NO:
- 2, an HCDR 2 comprising the amino acid sequence of SEQ ID NO:
- 3, and an HCDR 3 comprising the amino acid sequence of SEQ ID NO:
- 5, and a VL comprising an LCDR 1 comprising the amino acid sequence of SEQ ID NO:
- 8, an LCDR 2 comprising the amino acid sequence of SEQ ID NO:
- 9, and an LCDR 3 comprising the amino acid sequence of SEQ ID NO:
- 10,
- (ii) a second antigen binding domain capable of specific binding to FolR1, and
- (iii) a third antigen binding domain capable of specific binding to FolR1, wherein the second and the third antigen binding domains each comprise a VH comprising a HCDR 1 of SEQ ID NO:
- 124, a HCDR 2 of SEQ ID NO:
- 125, and a HCDR 3 of SEQ ID NO:
- 126, and a VL comprising a LCDR 1 of SEQ ID NO:
- 8, a LCDR 2 of SEQ ID NO:
- 9 and a LCDR 3 of SEQ ID NO:
- 10;
- wherein the first, second, and third antigen binding domains are each a Fab molecule, wherein the second and third are each a conventional Fab molecule;
- wherein in the first antigen binding domain the variable domains VL and VH of the Fab light chain and the Fab heavy chain are replaced by each other;
- wherein in each of the second and the third antigen binding domains:
- (a) in the constant domain CL, the amino acid at position 124 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R), or histidine (H) (numbering according to Kabat), and
- (b) in the constant domain CH1 the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index);
- wherein:
- (a) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain and the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or
- (b) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain and the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain;
- and the third antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain,
- wherein the bispecific antibody comprises an Fc domain composed of a first and a second subunit;
- and
- wherein the Fc domain is an IgG comprising a modification promoting the association of the first and the second subunit of the Fc domain and further comprising one or more amino acid substitutions that reduces binding to an Fc receptor and/or reduces an effector function.
Dependencies are inferred from the claim text.